Plasmodium falciparum drug resistance in West Africa. 1986

P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila

UI MeSH Term Description Entries
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011803 Quinine An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. Biquinate,Legatrim,Myoquin,Quinamm,Quinbisan,Quinbisul,Quindan,Quinimax,Quinine Bisulfate,Quinine Hydrochloride,Quinine Lafran,Quinine Sulfate,Quinine Sulphate,Quinine-Odan,Quinoctal,Quinson,Quinsul,Strema,Surquina,Bisulfate, Quinine,Hydrochloride, Quinine,Sulfate, Quinine,Sulphate, Quinine
D011804 Quinolines
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D000354 Africa, Western The geographical area of Africa comprising BENIN; BURKINA FASO; CABO VERDE, COTE D'IVOIRE (formerly Ivory Coast); GAMBIA; GHANA; GUINEA; GUINEA-BISSAU; LIBERIA; MALI; MAURITANIA; NIGER; NIGERIA; SENEGAL; SIERRA LEONE; and TOGO. Africa, West,West Africa,Western Africa
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D015767 Mefloquine A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects. Lariam,Mefloquine Hydrochloride,Mephloquine,Ro-21-5998-001,WR-142,490,WR-177,602,Ro 21 5998 001,Ro215998001,WR 142,490,WR 177,602,WR142,490,WR177,602

Related Publications

P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
March 1998, Presse medicale (Paris, France : 1983),
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
January 1989, Bulletin de la Societe de pathologie exotique et de ses filiales,
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
April 1994, Lancet (London, England),
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
March 1986, Archives de l'Institut Pasteur de Tunis,
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
August 2018, Emerging infectious diseases,
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
January 1987, MMWR. Morbidity and mortality weekly report,
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
April 2001, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
January 1966, Bulletin of the World Health Organization,
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
February 1988, Presse medicale (Paris, France : 1983),
P Druilhe, and P Brasseur, and O Brandicourt, and J Kouamouo, and D Richard-Lenoble, and F Diouf, and F Gay, and R S Moyou, and M Danis, and M Y Kombila
January 1984, Archives de l'Institut Pasteur de Madagascar,
Copied contents to your clipboard!